SCHEMBL3577979

SCHEMBL3577979

Cc1ccc(S(=O)(=O)O)c(CCCCC(C)CCCC(C)CCCC(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.37
PTPN1 P18031 1/20 0.37
CDC25B P30305 1/20 0.37
LMNA P02545 1/20 0.37
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
MEN1 O00255 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGS1 P23219 1/20 0.33
PDE4A P27815 1/20 0.33
SNCA P37840 1/20 0.33
PDE3A Q14432 1/20 0.33
BLM P54132 1/20 0.33
FUT7 Q11130 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3575731 1.00 PTPN2 (0.37) PTPN2PTPN1CDC25BLMNAPSEN1
SCHEMBL10604810 0.93 PTPN2 (0.38) PTPN2PTPN1CDC25BLMNAPSEN1
SCHEMBL3889264 0.93 FUT7 (0.38) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL31588190 0.93 FUT7 (0.38) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL7028791 0.90 PSEN1 (0.37) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL24225901 0.88 POLB (0.38) LMNAMEN1CYP3A4ALOX15KMT2A
SCHEMBL11258842 0.88 NR3C1 (0.33) LMNAMEN1CYP3A4ALOX15KMT2A
SCHEMBL9812248 0.87 GAA (0.32) LMNAMEN1KMT2AALDH1A1GAA
SCHEMBL20599447 0.84 ALDH1A1 (0.36) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL31303555 0.84 GAA (0.36) LMNAMEN1CYP3A4ALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846903-B2 cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2010-12-07 US disclosed
US-20080113923-A1 Type II Cubic Liquid Crystal Composition NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) 2008-05-15 US disclosed
EP-1813287-A1 TYPE II CUBIC LIQUID CRYSTAL COMPOSITION National Institute of Advanced Industrial Science and Technology (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113923-A1 Type II Cubic Liquid Crystal Composition AQP1, AQP3, SCO2 PTPN2 3866/4885PTPN1 4309/4885CDC25B 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.